ZA201403735B - Pharmaceutical formulations comprising atorvastatin and glimepiride - Google Patents

Pharmaceutical formulations comprising atorvastatin and glimepiride

Info

Publication number
ZA201403735B
ZA201403735B ZA2014/03735A ZA201403735A ZA201403735B ZA 201403735 B ZA201403735 B ZA 201403735B ZA 2014/03735 A ZA2014/03735 A ZA 2014/03735A ZA 201403735 A ZA201403735 A ZA 201403735A ZA 201403735 B ZA201403735 B ZA 201403735B
Authority
ZA
South Africa
Prior art keywords
glimepiride
atorvastatin
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
ZA2014/03735A
Other languages
English (en)
Inventor
Singh Raghuvanshi Rajeev
Dubey Rajesh
Kolluri Maheshwar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of ZA201403735B publication Critical patent/ZA201403735B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2014/03735A 2011-11-15 2014-05-22 Pharmaceutical formulations comprising atorvastatin and glimepiride ZA201403735B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3920CH2011 2011-11-15
US201261582566P 2012-01-03 2012-01-03
PCT/IB2012/002860 WO2013072770A2 (en) 2011-11-15 2012-11-14 Pharmaceutical formulations comprising atorvastatin and glimepiride

Publications (1)

Publication Number Publication Date
ZA201403735B true ZA201403735B (en) 2015-12-23

Family

ID=48430284

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03735A ZA201403735B (en) 2011-11-15 2014-05-22 Pharmaceutical formulations comprising atorvastatin and glimepiride

Country Status (5)

Country Link
EP (1) EP2779999A2 (de)
IN (1) IN2014CN04119A (de)
RU (1) RU2014124118A (de)
WO (1) WO2013072770A2 (de)
ZA (1) ZA201403735B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181532A1 (en) * 2020-05-18 2023-06-15 Board Of Regents, The University Of Texas System Granules for 3d printing technology
CN112618499B (zh) * 2020-12-24 2022-09-30 石药集团欧意药业有限公司 一种格列美脲分散片剂组合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3320582A1 (de) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
CZ294108B6 (cs) 1995-07-17 2004-10-13 Warner@Lambertácompany Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
ATE524163T1 (de) 2000-04-10 2011-09-15 Teva Pharma Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
AU2000250960A1 (en) 2000-06-09 2001-12-17 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
CZ20023826A3 (cs) 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
PE20020323A1 (es) 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1336405A1 (de) 2002-02-14 2003-08-20 Ranbaxy Laboratories, Ltd. Atorvastatin Zubereitungen stabilisiert mit Alkalimetalladditionen
US20030171407A1 (en) 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
CA2385529A1 (en) 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
SI21400A (sl) 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
WO2006006021A2 (en) 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
KR20070106680A (ko) 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
US8623405B2 (en) 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
US20100034885A1 (en) * 2005-06-10 2010-02-11 Combino Pharm, S.L. Formulations containing glimepiride and/or its salts
CN101103990A (zh) * 2006-07-14 2008-01-16 北京华安佛医药研究中心有限公司 含有磺脲类降糖药物和他汀类降脂药物的组合物
EP2081554A2 (de) 2006-09-27 2009-07-29 Dr. Reddy's Laboratories Ltd. Pharmazeutische atorvastatin-zusammensetzungen
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions

Also Published As

Publication number Publication date
WO2013072770A2 (en) 2013-05-23
IN2014CN04119A (de) 2015-07-10
RU2014124118A (ru) 2015-12-27
WO2013072770A3 (en) 2013-10-24
EP2779999A2 (de) 2014-09-24

Similar Documents

Publication Publication Date Title
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
HK1215948A1 (zh) 醯胺及其醫藥用途
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑
HRP20181896T1 (hr) Farmaceutske formulacije
EP2718283A4 (de) Indazol- und pyrrolopyridin-derivat sowie pharmazeutische verwendung davon
GB2486567B (en) Pharmaceutical formulation
HK1198137A1 (en) Disinfecting formulations and uses thereof
EP2775831A4 (de) Pharmazeutische zusammensetzungen und verwendungen davon
EP2597084A4 (de) N-hydroxyformamidderivat und arzneimittel damit
HK1208676A1 (en) Novel benzazepine derivative and pharmaceutical use thereof
HRP20141173T1 (hr) Medikament koji sadrži miramistin
ZA201403735B (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
HK1209339A1 (en) Pharmaceutical formulations
IL227905A0 (en) Toroidal pharmaceutical compositions
EP2668961A4 (de) Pharmazeutisches kombinationspräparat
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
GB201112578D0 (en) Pharmaceutical preparation and use
GB201111577D0 (en) Pharmaceutical formulations
PL390620A1 (pl) Preparat farmaceutyczny
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
IL227250A (en) Pain-relieving compounds and pharmaceuticals containing them
ZA201105275B (en) Pharmaceutical formulation containing atorvastatin and method for the preparation thereof
ZA201301851B (en) Pharmaceutical combinations